-
前列腺癌作为一种激素相关且骨转移发生率极高的恶性肿瘤,被认为是目前世界范围内男性人群最受关注的医疗问题之一。在美国,2015年前列腺癌发病率在男性恶性肿瘤中居第一位(26%),病死率居第二位(9%)[1],仅次于肺癌。在亚洲,前列腺癌的发病率远远低于欧美,但近年来呈现迅速上升趋势。在我国,前列腺癌自2008年起已成为泌尿系统中发病率最高的恶性肿瘤。2009年,其发病率达到9.92/10万,在男性恶性肿瘤发病率排名中居第6位;病死率达到4.19/10万,居第9位[2-3]。1994年至2002年,前列腺癌发病率每年增长13.4%[4]。发病率和病死率的不断增长及其多种治疗方法的可能性促使前列腺癌治疗方面的研究进展迅速,镭-223氯化物就是其中备受瞩目的一种。
镭-223氯化物治疗去势抵抗性前列腺癌骨转移的研究进展
Development in the study of radium-223 chloride for treating castration-resistant prostate carcinoma with bone metastases
-
摘要: 近年来,全世界前列腺癌的发病率和病死率不断增长,各种治疗方法的研究也进展迅速。镭-223发射的重α粒子(具有<100 μm的超短波)靶向作用于骨转移部位和周围新骨生长区域。镭-223氯化物在药物临床试验中以稳定的安全性显著降低了患者的病死率,成为近来被寄予厚望的转移性去势抵抗性前列腺癌(CRPC)治疗领域的“主角”。2013年美国食品药品管理局已批准镭-223氯化物用于治疗有症状的骨转移、未发现内脏转移的CRPC患者。未来其联合治疗方案将会是研究的重点。Abstract: Prostate carcinoma rates and mortalities are increasing worldwide. The therapeutic landscape of castration-resistant prostate carcinoma(CRPC) has changed rapidly. Radium-223 chloride, which is a radiopharmaceutical agent, targets bone metastasis by emitting high-energy alpha-particles with extremely short range(< 100 μm). This chemical is effective in reducing mortality without increasing toxicity. Thus, this agent has the potential to become a new alternative for treating patients with CRPC. The Food and Drug Administration approved radium-223 dichloride for treating patients with CRPC, symptomatic bone metastases, and unknown visceral metastatic disease in 2013. Therefore, combination and sequencing strategies will be future research directions.
-
Key words:
- Radium /
- Chlorides /
- Prostatic Neoplasms /
- Neoplasms metastasis
-
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1):5-29. doi: 10.3322/caac.21254 [2] 韩苏军, 张思维, 陈万青, 等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志, 2013, 18(4):330-334. doi: 10.3969/j.issn.1009-0460.2013.04.009
[3] 赫捷, 陈万青. 2012中国肿瘤登记年报[M].北京:军事医学科学出版社, 2012.
[4] Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates[J]. Eur Urol, 2012, 61(6):1079-1092. doi: 10.1016/j.eururo.2012.02.054 [5] Chi KN, Bjartell A, Dearnaley D, et al. Castration-resistant Prostate Cancer:From New Pathophysiology to New Treatment Targets[J]. Eur Urol, 2009, 56(4):594-605. [6] Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1:screening, diagnosis, and treatment of clinically localised disease[J]. Eur Urol, 2011, 59(1):61-71. [7] Chin JL, Srigley J, Mayhew LA, et al. Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management:evidentiary base[J]. Can Urol Assoc J, 2010, 4(1):13-25. doi: 10.5489/cuaj.08105 [8] Sgouros G, Roeske JC, McDevitt MR, et al. MIRD pamphlet No. 22(abridged):radiobiology and dosimetry of alpha-Particle emitters for targeted radionuclide therapy[J]. J Nucl Med, 2010, 51(2):311-328. doi: 10.2967/jnumed.108.058651 [9] Pandit-Taskar N, Larson SM, Carrasquillo JA. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1:α therapy with 223Ra-dichloride[J]. J Nucl Med, 2014, 55(2):268-274. [10] Henriksen G, Breistøl K, Bruland ØS, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model[J]. Cancer Res, 2002, 62(11):3120-3125. [11] Hobbs RF, Song H, Watchman CJ, et al. A bone marrow toxicity model for Ra-223 alpha-emitter radiopharmaceutical therapy[J]. Phys Med Biol, 2012, 57(10):3207-3222. doi: 10.1088/0031-9155/57/10/3207 [12] Neuman WF, Hursh JB, Boyd J, et al. On the mechanism of skeletal fixation of radium[J]. Ann N Y Acad Sci, 1955, 62(6):125-136. doi: 10.1111/j.1749-6632.1955.tb35369.x [13] Parker C, Heinrich D, O′sullivan JM, et al. Overall survival benefit of radium-223 chloride(Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer(CRPC):a phase Ⅲ randomized trial(ALSYMPCA)[Abstract 1LBA][J]. Eur J Cancer, 2011, 47(suppl 2):3. [14] Kluetz PG, Pierce W, Maher VE, et al. Radium Ra 223 dichloride injection:U. S. food and Drug Administration drug approval summary[J]. Clin Cancer Res, 2014, 20(1):9-14. doi: 10.1158/1078-0432.CCR-13-2665 [15] Nilsson S, Larsen RH, Fossả SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases[J]. Clin Cancer Res, 2005, 11(12):4451-4459. doi: 10.1158/1078-0432.CCR-04-2244 [16] Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer:a randomised, multicentre, placebo-controlled phase Ⅱ study[J]. Lancet Oncol, 2007, 8(7):587-594. doi: 10.1016/S1470-2045(07)70147-X [17] Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase Ⅱ study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer[J]. Eur J Cancer, 2012, 48(5):678-686. doi: 10.1016/j.ejca.2011.12.023 [18] Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer[J]. N Engl J Med, 2013, 369(3):213-223. doi: 10.1056/NEJMoa1213755 [19] Dauer LT, Williamson MJ, Humm J, et al. Radiation safety considerations for the use of 223RaCl DE in men with castration-resistant prostate cancer[J]. Health Phys, 2014, 106(4):494-504. doi: 10.1097/HP.0b013e3182a82b37 [20] Coleman R, Aksnes AK, Naume B, et al. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease[J]. Breast Cancer Res Treat, 2014, 145(2):411-418. doi: 10.1007/s10549-014-2939-1 [21] Takalkar A, Adams S, Subbiah V. Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone[J]. Exp Hematol Oncol, 2014, 3:23. doi: 10.1186/2162-3619-3-23 [22] Algeta ASA. A study of Alpharadin with docetaxel in patients with bone metastasis from castration-resistant prostate cancer(CRPC)[DB/OL]. US National Institutes of Health, ClinicalTrials. gov, 2012[2015-01-12]. http://www.clinicaltrials.gov/ct2/show/NCT01106352. [23] Clark MJ, Harris N, Griebsch I, et al. Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union[J]. Health Qual Life Outcomes, 2014, 12:104. doi: 10.1186/s12955-014-0104-5 [24] Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer:results of a phase 3, randomised, placebo-controlled trial[J]. Lancet, 2012, 379(9810):39-46. doi: 10.1016/S0140-6736(11)61226-9 [25] Cheever MA, Higano CS. PROVENGE(Sipuleucel-T) in prostate cancer:the first FDA-approved therapeutic cancer vaccine[J]. Clin Cancer Res, 2011, 17(11):3520-3526. doi: 10.1158/1078-0432.CCR-10-3126
计量
- 文章访问数: 3377
- HTML全文浏览量: 2237
- PDF下载量: 14